Acesso livre
Acesso livre

Destaques

Metanálise de estudos randomizados | Clopidogrel é melhor que aspirina na prevenção secundária de eventos cardiovasculares.

1 Abr, 2022 | 12:25h

P2Y12 Inhibitor versus Aspirin Monotherapy for Secondary Prevention of Cardiovascular Events: Meta-Analysis of Randomized Trials – European Heart Journal Open

Comentário: Clopidogrel Superior to ‘Divine’ Aspirin Monotherapy in Secondary Prevention – TCTMD

 

Comentário no Twitter

 

Risco de reinfecções por SARS-CoV-2 em crianças: um estudo de vigilância nacional prospectiva na Inglaterra.

1 Abr, 2022 | 12:24h

Risk of SARS-CoV-2 reinfections in children: a prospective national surveillance study between January, 2020, and July, 2021, in England – The Lancet Child & Adolescent Health

Comentário convidado: Importance of understanding the reinfection risk of COVID-19 in children – The Lancet Child & Adolescent Health

 

Comentário no Twitter

 

Uma revisão narrativa sobre a abordagem do uso de antibióticos em pacientes ventilados apresentando organismos multirresistentes em amostras respiratórias – tratar ou não tratar?

1 Abr, 2022 | 12:22h

A Narrative Review on the Approach to Antimicrobial Use in Ventilated Patients with Multidrug Resistant Organisms in Respiratory Samples—To Treat or Not to Treat? That Is the Question – Antibiotics

 

Comentário no Twitter

 

[Preprint] Estudo de coorte retrospectiva | 2º reforço de vacina e mortalidade por Covid-19 em adultos de 60 a 100 anos de idade.

31 Mar, 2022 | 13:44h

Second Booster Vaccine and Covid-19 Mortality in Adults 60 to 100 Years Old – Research Square

Comentários:

Huge Study Finds Second COVID-19 Booster is ‘Life-saving’ for Over 60s – Health Policy Watch

Fourth COVID-19 vaccine dose substantially reduces mortality in the elderly – News Medical

EUA aprovam 2ª dose de reforço contra Covid-19 para pessoas de 50 anos de idade ou mais e indivíduos imunocomprometidos.

31 Mar, 2022 | 13:41h

U.S. approves second Covid-19 booster for people 50 and older – STAT

FDA OKs second COVID booster shot for older Americans – CIDRAP

Ver diretriz: Coronavirus (COVID-19) Update: FDA Authorizes Second Booster Dose of Two COVID-19 Vaccines for Older and Immunocompromised Individuals – U.S. Food & Drug Administration

Estudo de coorte | Desfechos de curto prazo da monoterapia com corticosteroide na síndrome inflamatória multissistêmica em crianças.

31 Mar, 2022 | 13:40h

Short-term Outcomes of Corticosteroid Monotherapy in Multisystem Inflammatory Syndrome in Children – JAMA Pediatrics

 

Comentário no Twitter

 

Estudo RECOVERY – 2 anos.

31 Mar, 2022 | 13:38h

The RECOVERY Trial – two years on – University of Oxford

Conteúdos relacionados:

How the UK found the first effective Covid-19 treatment — and saved a million lives (about the RECOVERY trial and the effects of Dexamethasone)

Covid: The London bus trip that saved maybe a million lives (about the creation of the RECOVERY Trial)

Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19 – Recovery Trial

[Preprint] RECOVERY trial shows Baricitinib reduces deaths in patients hospitalized with COVID-19.

RCT: CPAP improved outcomes in patients with acute hypoxemic respiratory failure due to COVID-19, but high-flow nasal oxygen was not better than conventional oxygen therapy.

RECOVERY Trial: No benefit from convalescent plasma in patients admitted to hospital with COVID-19.

RECOVERY Trial: Aspirin as an add-on therapy did not reduce mortality in patients hospitalized with COVID-19.

RECOVERY trial: In hospitalized COVID-19 patients with hypoxia and systemic inflammation (C-reactive protein ≥75 mg/L), tocilizumab improved survival and other clinical outcomes

RECOVERY trial: Azithromycin not beneficial for patients admitted to hospital with COVID-19

[Preprint] RECOVERY trial finds Regeneron’s monoclonal antibody combination reduces deaths for hospitalized COVID-19 patients who have not mounted their own immune response.

RECOVERY trial: Effect of hydroxychloroquine in hospitalized patients with Covid-19

Randomized trial: Lopinavir–ritonavir not beneficial for patients admitted to hospital with COVID-19

 

Comentário no Twitter

 

Relato de caso | Os danos da antibioticoprofilaxia pós-operatória.

31 Mar, 2022 | 13:36h

The Harms of Postoperative Antibiotic Prophylaxis: A Teachable Moment – JAMA Internal Medicine (gratuito por tempo limitado)

Bacteriemia por S. aureus complicada e não complicada: uma pesquisa internacional Delphi entre especialistas em doenças infecciosas sobre definições e tratamento.

31 Mar, 2022 | 13:34h

Complicated and uncomplicated S. aureus bacteremia: an international Delphi survey among infectious diseases experts on definitions and treatment – Clinical Microbiology and Infection

Posicionamento científico AHA/ASA | Tratamento endovascular e trombólise para AVC isquêmico agudo em pacientes com incapacidade premórbida ou demência.

31 Mar, 2022 | 13:32h

Endovascular Treatment and Thrombolysis for Acute Ischemic Stroke in Patients With Premorbid Disability or Dementia: A Scientific Statement From the American Heart Association/American Stroke Association – Stroke

Comunicado de imprensa: Stroke treatments safe and effective for people with existing disability or dementia – American Heart Association

 

Comentário no Twitter (fio – clique para saber mais)

 

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.